A targeted drug combination delays advanced prostate cancer in men with specific DNA repair gene mutations. A large international study led by researchers at UCL has found that a new combination of dr ...

A drug combination already used in advanced prostate cancer now appears to significantly extend survival when given earlier.

Outside prostate cancer, Truqap is FDA-approved with fulvestrant (Faslodex) for patients with hormone receptor-positive, HER2 ...

Novartis has shared detailed data showing its radioligand therapy Pluvicto could slow the progression of certain hormone-sensitive prostate cancers ahead of a planned application with the FDA. | ...

Prostate cancer is the most common form of cancer in the UK, according to Prostate Cancer UK. Cancer Research UK says ...

Two cancer experts go head to head, arguing the case for and against a targeted prostate cancer screening programme.

Discover how rectal spacers revolutionize prostate cancer treatment by reducing side effects and enhancing radiation dose ...

The former PM is among those in favour of targeted screening for men most at risk, but some medical experts are sceptical.

There is no single, diagnostic test. Doctors make a diagnosis based on various measures. This can include a prostate-specific ...

Dr. Wallen: When the prostate cancer is only in the prostate and hasn't spread elsewhere, the standard of care treatments are ...

A new study led by University of Manchester scientists has identified genetic variants that make some patients more sensitive ...

A targeted cancer drug niraparib, used in combination with hormone therapy, was found to reduce the risk of prostate tumor ...